Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600117391) titled 'Pasritamig With Docetaxel vs Docetaxel in Metastatic Castration-resistant Prostate Cancer (mCRPC)' on Jan. 23.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: West China Hospital of Sichuan University
Condition:
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Intervention:
Control group:Docetaxel
Recruitment Status: Not Recruiting
Phase: 3
Date of First Enrollment: 2026-02-01
Target Sample Size: Control group:400;Experimental group:400;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=306229
Published by HT Digital C...